Gyre Therapeutics Inc (STU:L9S)
€ 13.6 -0.1 (-0.73%) Market Cap: 1.33 Bil Enterprise Value: 1.30 Bil PE Ratio: 0 PB Ratio: 21.33 GF Score: 30/100

Catalyst Biosciences Inc R&D Day Transcript

Jul 19, 2021 / 04:00PM GMT
Operator

Good afternoon, and welcome to the Catalyst Biosciences R&D Day. (Operator Instructions). As a reminder, this call is being recorded, and a replay will be made available on the Catalyst Biosciences website following the conclusion of the event. I'd now like to turn the call over to Monique Kosse of LifeSci Advisors. Please go ahead, Monique.

Monique Kosse
LifeSci Advisors, LLC - MD

Thank you, Tara. Before we begin, I would like to remind you of the company's forward-looking statements found here and in their filings with the SEC. I would like to advise listeners that comments made today on today's call may reflect forward-looking statements that are related to such matters as Catalyst Biosciences clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives and financial projections, among others.

While management believes that its assumptions and expectations and projections are reasonable in the view of the currently available information,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot